The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, ...

Norgine has announced that Swissmedic has approved the registration of IFINWIL (eflornithine) as a monotherapy for treating paediatric patients with high-risk neuroblastoma (HRNB) from one year of age ...

Swissmedic has introduced a fast-track review process for clinical trial applications, aiming to speed up access to ...

Malaria caused 597,000 deaths worldwide in 2023, with children under 5 accounting for 76 percent of all malaria deaths in the ...

Swissmedic approves Novartis’ Coartem Baby to treat malaria in newborns and young infants: Basel Thursday, July 10, 2025, 11:00 Hrs [IST] Novartis announced Coartem (artemether- ...

Swissmedic approves Norgine’s Ifinwil for children diagnosed with high-risk neuroblastoma: Uxbridge, UK Thursday, July 10, 2025, 17:00 Hrs [IST] Norgine, a leading European spec ...

IFINWIL®: now approved in Switzerland1 <li /> Nine out of 10 cases of neuroblastoma occur in children under the age ...

IFINWIL®: now approved in Switzerland1Nine out of 10 cases of neuroblastoma occur in children under the age of five2The average survival rate of children with HRNB is only 50%2UXBRIDGE, England ...

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

The newly approved medication, Coartem Baby, is a combination of two antimalarials. It is a lower dose version of a tablet ...